logo-loader
viewSativa Group PLC

Sativa capitalises on first-mover advantage in UK medicinal cannabis

Snapshot

  • UK’s first medicinal cannabis investment vehicle
  • Now operates with two fully trading UK businesses
  • Commercial deals clinched with suppliers of cannabis oil
  • Sativa to roll out CBD wellness retail centres and clinics
Sativa

Quick facts: Sativa Group PLC

Price: 5.65 GBX

NEX:SATI
Market: NEX
Market Cap: -
Follow

What Sativa does

Sativa Group PLC (NEX:SATI) is Britain's first medicinal cannabis investment vehicle and is now an operating company with two fully trading UK businesses.

Listed on the NEX exchange in March 2018, Sativa was set up to make investments into Canada-based cannabis companies where the drug is now approved for medicinal and recreational use. 

Since the legalisation of medicinal cannabis in the UK in late 2018, Sativa has capitalised on its first-mover advantage to become a seed-to-consumer medicinal cannabis and cannabidiol (CBD) wellness business. 

It is now focused on the sourcing of raw material, advanced extraction, manufacture, testing, distribution, and research & development of cannabis products.

In October 2019, the company received a controlled drug licence from the UK Home Office, allowing it to produce and supply cannabis at its headquarters in Somerset.

The medicinal cannabis firm said it will immediately begin a research partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.

 

What Sativa owns

Sativa’s investments include: Canada-based pharmaceutical firm, Veritas Pharma.; Canada pharma-tech business, Rapid Dose Therapeutics, which owns the QuickStrip oral dissolving cannabis strips; and a 60% stake in a joint venture with Germany's Lexamed GmbH.

Its two operating subsidiaries are testing facility, PhytoVista Laboratories, and George Botanicals, which develops, manufactures and distributes low-Tetrahydrocannabinol (THC) and CBD wellness products.

 

What the CEO says: Henry Lees-Buckley

"The Goodbody CBD Wellness business completed its three-store pilot phase and is poised to roll-out its franchise model. 

"With the George Botanicals brand and PhytoVista laboratories also performing well, prospects look good." 

 

Video

 

Inflexion points:

  • In November, Sativa said that it was exploring a potential listing on AIM in 2020
  • The company has appointed Clive Page, professor of pharmacology at King's College London, to its medical advisory board
  • In October, the firm inked a deal with a company that helps some of the world’s major consumer brands increase their market share here in the UK. SHS Sales & Marketing, which counts among its customers Mars and Colgate, will market Sativa’s Goodbody Botanicals CBD range
  • Sativa has signed commercial offtake agreements with two suppliers of cannabis oil for the manufacture of CBD products in the UK. These suppliers are Swiss firm, Alponics, and Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Sativa Group is setting up for the future after Home Office...

Sativa Group (LON: SATI) CEO Henry Lees-Buckley joined Steve Darling from Proactive Vancouver to discuss the UK’s first listed Cannabis Company. This company focussing on 4 key business areas. Lee-Buckley talking about those areas and why he feels the UK is the right place at the right time...

on 5/11/19

2 min read